(VIANEWS) – TEXAF (TEXF.BR), SANOFI (SAN.PA), EQUASENS (EQS.PA) are the highest payout ratio stocks on this list.
We have collected information regarding stocks with the highest payout ratio up to now. The payout ratio in itself isn’t a promise of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. TEXAF (TEXF.BR)
74.72% Payout Ratio
Texaf S.A. develops, owns, and leases real estate properties in Kinshasa. It operates through Real Estate, Digital, and Quarries segments. The company's portfolio comprises 333 homes, including 53 villas and 280 apartments with a residential area of 62,192 square meters; 26,313 square meters of office and retail space; and 30,146 square meters of warehouses, as well as TEXAF digital campus. It also supplies sandstones for use in concrete production, asphalt for roads, and civil engineering projects. The company was founded in 1925 and is headquartered in Brussels, Belgium. Texaf S.A. is a subsidiary of Société Financière Africaine.
Earnings Per Share
As for profitability, TEXAF has a trailing twelve months EPS of €1.27.
PE Ratio
TEXAF has a trailing twelve months price to earnings ratio of 27.92. Meaning, the purchaser of the share is investing €27.92 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.91%.
Volume
Today’s last reported volume for TEXAF is 60 which is 86.54% below its average volume of 446.
2. SANOFI (SAN.PA)
50% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €9.68.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 9.33. Meaning, the purchaser of the share is investing €9.33 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.77%.
Moving Average
SANOFI’s worth is higher than its 50-day moving average of €89.65 and higher than its 200-day moving average of €88.95.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 1.5% and a drop 1.2% for the next.
3. EQUASENS (EQS.PA)
37.7% Payout Ratio
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.59%.
Sales Growth
EQUASENS’s sales growth is 11.3% for the ongoing quarter and 11.3% for the next.
Yearly Top and Bottom Value
EQUASENS’s stock is valued at €73.30 at 06:10 EST, way under its 52-week high of €90.60 and way higher than its 52-week low of €57.80.
Moving Average
EQUASENS’s worth is below its 50-day moving average of €77.40 and under its 200-day moving average of €76.13.
Volume
Today’s last reported volume for EQUASENS is 3584 which is 7.75% above its average volume of 3326.
4. CRH PLC ord (CRG.IR)
33.8% Payout Ratio
CRH plc, through its subsidiaries, manufactures and distributes building materials. It operates in three segments: Americas Materials, Europe Materials, and Building Products. The company manufactures and supplies cement, lime, aggregates, precast, ready mixed concrete, and asphalt products; concrete masonry and hardscape products comprising pavers, blocks and kerbs, retaining walls, and related patio products; and glass and glazing products, including architectural glass, custom-engineered curtain and window walls, architectural windows, storefront systems, doors, skylights, and architectural hardware. It also offers precast concrete and polymer-based products, such as underground vaults, drainage pipes and structures, utility enclosures, and modular precast structures to the water, energy, communication, transportation, and building structures markets; and construction accessories, such as anchoring, fixing, and connection solutions, as well as lifting systems, formwork accessories, and other accessories used in construction applications. In addition, the company offers network access products, which include composite access chambers, covers, passive safety systems, retention sockets, sealants, and meter boxes; and paving and construction services. Further, it provides building and civil engineering contracting, contract surfacing, operates logistics and owned railway infrastructure; sells and distributes cement; and supplies access chambers and ducting products. It serves governments, contractors, homebuilders, homeowners, and sub-contractors. The company operates primarily in the Republic of Ireland, the United Kingdom, the rest of Europe, the United States, and internationally. CRH plc was founded in 1936 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, CRH PLC ord has a trailing twelve months EPS of €1.18.
PE Ratio
CRH PLC ord has a trailing twelve months price to earnings ratio of 41.41. Meaning, the purchaser of the share is investing €41.41 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.41%.
Yearly Top and Bottom Value
CRH PLC ord’s stock is valued at €48.70 at 06:10 EST, below its 52-week high of €49.74 and way above its 52-week low of €31.80.
Moving Average
CRH PLC ord’s worth is way higher than its 50-day moving average of €42.15 and way above its 200-day moving average of €37.52.
Volume
Today’s last reported volume for CRH PLC ord is 525668 which is 64.55% below its average volume of 1483000.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.7%, now sitting on 32.72B for the twelve trailing months.
